As of November 7, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Rapt Therapeutics, Inc. The largest reported stake is Redmile Group, LLC's, at 9.9%. 12 filings are on record since August 14, 2025 (Schedule 13G/A, August 14, 2025).
Sell to companies like Rapt Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: RTW Investments, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-15
- · Holder: RTW Investments, LP · Percent: 5.9% · SCHEDULE 13G/A
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 110,448 · Sole dispositive: 0 · Shared dispositive: 110,448 · SCHEDULE 13G/A, 2026-02-13
- · Holder: Glazer Capital, LLC · Percent: 5.36% · SCHEDULE 13G
Rapt Therapeutics, Inc. has 12 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Redmile Group, LLC | 9.9% | 1,765,303 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| ForGrowth III PA B.V. | 7.4% | 1,833,333 | SCHEDULE 13G, 2025-10-29 | 2025-10-23 |
| Glazer Capital, LLC | 5.36% | 1,486,094 | SCHEDULE 13G, 2026-02-09 | 2026-02-02 |
| The Vanguard Group | 4.2% | 696,188 | SCHEDULE 13G/A, 2025-10-30 | 2025-09-30 |
| Nantahala Capital Management, LLC | 3.77% | 623,282 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Deep Track Capital, LP | 0.4% | 110,448 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Orbimed Advisors LLC | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| RTW Investments, LP | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Rapt Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Rapt Therapeutics, Inc. and the records around it.
The people at Rapt Therapeutics, Inc.
- William Rieflin is also named on 1 other Form D filing: Lycia Therapeutics, Inc. (Jun 2026)
Companies that share a holder
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Vor Biopharma Inc. (Dec 2025), Crescent Biopharma, Inc. (Dec 2025)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch Rapt Therapeutics, Inc.
Get an email when Rapt Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rapt Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Rapt Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rapt Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 0 | 110,448 | 0 | 110,448 | SCHEDULE 13G/A, 2026-02-13 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 110,448 | 0 | 110,448 | SCHEDULE 13G/A, 2026-02-13 |
| David Kroin | 0 | 110,448 | 0 | 110,448 | SCHEDULE 13G/A, 2026-02-13 |
| Orbimed Advisors LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| RTW Investments, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Roderick Wong | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies Rapt Therapeutics, Inc. by CUSIP 75382E109 and gives its principal executive office as 561 Eccles Avenue, South San Francisco, CA 94080 (SCHEDULE 13G/A, 2026-05-15).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Redmile Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2025-08-14 | Nantahala Capital Management, LLC | 5.75% | SCHEDULE 13G |
| 2025-10-29 | ForGrowth III PA B.V. | 7.4% | SCHEDULE 13G |
| 2025-10-30 | The Vanguard Group | 4.2% | SCHEDULE 13G/A |
| 2025-11-14 | Biotechnology Value Fund L P | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Orbimed Advisors LLC | 6.6% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Management, LLC | 3.77% | SCHEDULE 13G/A |
| 2026-02-09 | Glazer Capital, LLC | 5.36% | SCHEDULE 13G |
| 2026-02-13 | Deep Track Capital, LP | 0.4% | SCHEDULE 13G/A |
| 2026-02-17 | RTW Investments, LP | 5.9% | SCHEDULE 13G/A |
| 2026-05-15 | Orbimed Advisors LLC | 0% | SCHEDULE 13G/A |
| 2026-05-15 | RTW Investments, LP | 0% | SCHEDULE 13G/A |
Questions about who owns Rapt Therapeutics, Inc.
Who owns Rapt Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Rapt Therapeutics, Inc.: Redmile Group, LLC (9.9%, Schedule 13G/A, filed 2025-08-14), ForGrowth III PA B.V. (7.4%, Schedule 13G, filed 2025-10-29) and Glazer Capital, LLC (5.36%, Schedule 13G, filed 2026-02-09).
Who are the largest shareholders of Rapt Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Rapt Therapeutics, Inc. on this page are Redmile Group, LLC (9.9%), ForGrowth III PA B.V. (7.4%) and Glazer Capital, LLC (5.36%).
When did Redmile Group, LLC buy into Rapt Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Redmile Group, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Rapt Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 3, 2025 | Form D, private offering | $149.98M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Rapt Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.